Skip to content

SB3 Battery Life Observational Study

Clinical Impact of Longer Battery Life on Small Bowel Capsule Endoscopy: a Prospective Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02382705
Enrollment
57
Registered
2015-03-09
Start date
2015-02-28
Completion date
2017-02-28
Last updated
2019-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Capsule Endoscopy

Keywords

capsule endoscopy, battery life, completion rate, diagnostic yield

Brief summary

Capsule endoscopy (CE) is a non-invasive means of visualizing the small bowel. Common indications for CE include obscure gastrointestinal (GI) bleeding, inflammatory bowel disease like crohn's disease or ulcerative colitis, celiac disease, and polyposis syndrome. While CE has high diagnostic value for small bowel lesions, a significant limitation of this technology is the finite battery life which results in incomplete examination of the small bowel approximately 16.5% of the time. Numerous attempts of using pharmacological (e.g. prokinetics, purgatives) as well as non-pharmacological measures (e.g. real-time viewer, chewing gum) to improve completion rates, defined by entry of CE into the cecum, led to mixed results. Currently routine use of prokinetics (agents that speeds up gut motility) is not recommended. This study aims to determine whether longer battery of the newer generation capsule endoscopy system improves study completion rate and diagnostic yield.

Interventions

None listed

Sponsors

University of British Columbia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female age 19 or greater who are referred for small bowel capsule endoscopy * Willing and able to provide written informed consent

Exclusion criteria

* Unwillingness or inability to swallow pill * Known or suspected obstruction or bowel stricture * Endoscopic placement of capsule camera * Concomitant enrollment in a prospective study in the treatment arm receiving prokinetics for the purpose of enhancing bowel motility. (i.e. control arm not receiving any motility-enhancing agent can be included)

Design outcomes

Primary

MeasureTime frameDescription
Completion Rate (Rate at Which Small Bowel is Completely Examined)0.1 - 12 hoursrate at which small bowel is completely examined (capsule endoscopy enters cecum)

Secondary

MeasureTime frameDescription
Diagnostic Yield0.1 - 12 hoursrate at which a pathological finding is identified on capsule endoscopy
Gastric Transit Time0.1 - 12 hourstime it takes for capsule camera to traverse the stomach
Small Bowel Transit Time0.1 - 12 hourstimes it takes for capsule camera to traverse the entire small bowel.

Countries

Canada

Participant flow

Participants by arm

ArmCount
PillCam SB3EX
All participants in the study used the PillCam SB3EX for their capsule endoscopy
57
Total57

Baseline characteristics

CharacteristicPillCam SB3EX
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
15 Participants
Age, Categorical
Between 18 and 65 years
42 Participants
Age, Continuous53.6 years
STANDARD_DEVIATION 15.7
Race and Ethnicity Not Collected— Participants
Region of Enrollment
Canada
57 participants
Sex: Female, Male
Female
28 Participants
Sex: Female, Male
Male
29 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 57
serious
Total, serious adverse events
0 / 57

Outcome results

Primary

Completion Rate (Rate at Which Small Bowel is Completely Examined)

rate at which small bowel is completely examined (capsule endoscopy enters cecum)

Time frame: 0.1 - 12 hours

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
PillCam SB3EXCompletion Rate (Rate at Which Small Bowel is Completely Examined)57 Participants
Secondary

Diagnostic Yield

rate at which a pathological finding is identified on capsule endoscopy

Time frame: 0.1 - 12 hours

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
PillCam SB3EXDiagnostic Yield20 Participants
Secondary

Gastric Transit Time

time it takes for capsule camera to traverse the stomach

Time frame: 0.1 - 12 hours

ArmMeasureValue (MEAN)Dispersion
PillCam SB3EXGastric Transit Time37.6 minutesStandard Deviation 92.1
Secondary

Small Bowel Transit Time

times it takes for capsule camera to traverse the entire small bowel.

Time frame: 0.1 - 12 hours

ArmMeasureValue (MEAN)Dispersion
PillCam SB3EXSmall Bowel Transit Time232.1 minutesStandard Deviation 98.3

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026